NFKB1 and prostate carcinoma: A plausible explanation for this interference can be related to the antiandrogenic action (AR antagonist) of cimetidine since studies focusing on the effects of AR on NF-kB activity in the prostate cancer cell lines have demonstrated that NF-kB activity depends on the availability of androgens.